6 results on '"Bolignano, Davide"'
Search Results
2. Selenoprotein P-1 (SEPP1) as an Early Biomarker of Myocardial Injury in Patients Undergoing Cardiopulmonary Bypass.
- Author
-
Serraino, Giuseppe Filiberto, Bolignano, Davide, Jiritano, Federica, Coppolino, Giuseppe, Napolitano, Désirée, Zicarelli, Mariateresa, Pizzini, Patrizia, Cutrupi, Sebastiano, Testa, Alessandra, Spoto, Belinda, Andreucci, Michele, Mastroroberto, Pasquale, and Serra, Raffaele
- Subjects
- *
MYOCARDIAL injury , *CARDIOPULMONARY bypass , *SURGICAL complications , *BIOMARKERS , *CARDIAC surgery , *ENZYME-linked immunosorbent assay - Abstract
Background: Biomarkers development for prognostication or prediction of perioperative myocardial disease is critical for the evolution of treatment options in patients undergoing cardiac surgery. The aim of our prospective monocentric study was to investigate the role of selenoprotein 1 (SEEP 1) as a potential biomarker for assessing the risk of myocardial injury after cardiac surgery. Methods: Circulating SEPP1 was measured in the blood of 45 patients before surgery and at 4 h, 8 h and 12 h after CPB by enzyme-linked immunosorbent assay (ELISA); (3) Results: circulating SEPP-1 levels measured 4 h after surgery were strongly correlated with CK-MB levels measured at 48 h (R = 0.598, p < 0.0001) and at 72 h (R = 0.308, p = 0.05). Close correlations were also found between 4 h SEPP-1 and Hs-c troponin values measured at 24 h (R = 0.532, p < 0.0001), 48 h (R = 0.348, p = 0.01) and 72 h (R = 0.377, p = 0.02), as well as with cardiopulmonary bypass (CPB) (R = 0.389, p = 0.008) and cross-clamp time (R = 0.374, p = 0.001); (4) Conclusions: Early SEPP1 measurement after CPB may hold great potential for identifying cardiac surgery patients at risk of developing perioperative myocardial injury. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Spice Up Your Kidney: A Review on the Effects of Capsaicin in Renal Physiology and Disease
- Author
-
Musolino, Michela, primary, D’Agostino, Mario, additional, Zicarelli, Mariateresa, additional, Andreucci, Michele, additional, Coppolino, Giuseppe, additional, and Bolignano, Davide, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Urinary Post-Translationally Modified Fetuin-A (uPTM-FetA) in Chronic Kidney Disease Patients with and without Diabetic Kidney Disease.
- Author
-
Musolino, Michela, Greco, Marta, D'Agostino, Mario, Tripodi, Loredana, Misiti, Roberta, Dragone, Francesco, Cianfrone, Paola, Zicarelli, Mariateresa, Foti, Daniela Patrizia, Andreucci, Michele, Bolignano, Davide, and Coppolino, Giuseppe
- Subjects
CHRONIC kidney failure ,CHRONICALLY ill ,DIABETIC nephropathies ,PEOPLE with diabetes ,KIDNEY diseases ,POST-translational modification - Abstract
Background and Objectives: A novel post-translational modification (PTM) fragment derived from the cleavage of Fetuin-A (PTM-FetA) has recently emerged as a sensitive biomarker for kidney damage in diabetic patients, but evidence in other chronic renal diseases is lacking. In this pilot study, we aimed at evaluating the clinical significance of urinary PTM-FetA (uPTM-FetA) in a mixed cohort of patients with non-advanced chronic kidney disease (CKD) secondary to diabetic kidney disease (DKD) or other causes. Materials and Methods: We enrolled 47 adult patients with CKD (mean CKD-Epi 40.10 ± 16.5 mL/min/1.73 m
2 ) due to DKD (n = 34) or other etiology (n = 13). uPTM-FetA was measured in the urine using a commercially available ELISA kit. Fifteen healthy individuals served as controls. Results: Collectively, all CKD patients displayed remarkably higher levels of uPTM-FetA than controls (0.84 [0.10–1.15] vs. 29.68 [2.50–55.16] ng/mL p = 0.0005), but values were lower in non-DKD than in DKD patients (1.66 [0.09–4.19] vs. 13.9 [0.01–45.02] ng/mL; p = 0.01). uPTM-FetA showed a great diagnostic capacity at ROC analyses to identify the presence of CKD (AUC 0.776; p < 0.001) and, within CKD patients, to discriminate the diabetic and non-diabetic etiology (AUC 0.673; p = 0.02). At multivariate correlation analyses, proteinuria (β = 0.442; p = 0.02) and BMI (β = −0.334; p = 0.04) were the sole independent predictors of uPTM-FetA in this study population. Conclusions: uPTM-FetA could be a novel sensitive biomarker at the crossroad of chronic renal damage and metabolic dysfunction. Additionally, this biomarker could also represent a non-invasive, complementary tool for discriminating among different CKD etiologies (DKD vs. non-DKD) in difficult cases or when renal biopsy is not available. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
5. Sleep apnoea syndrome prevalence in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis.
- Author
-
Pisano, Anna, Zoccali, Carmine, Bolignano, Davide, D'Arrigo, Graziella, and Mallamaci, Francesca
- Subjects
CHRONIC kidney failure ,SLEEP apnea syndromes ,KIDNEY diseases ,CHRONICALLY ill - Abstract
Background Several studies have examined the frequency of sleep apnoea (SA) in patients with chronic kidney disease (CKD), reporting different prevalence rates. Our systematic review and meta-analysis aimed to define the clinical penetrance of SA in CKD and end-stage kidney disease (ESKD) patients. Methods Ovid-MEDLINE and PubMed databases were explored up to 5 June 2023 to identify studies providing SA prevalence in CKD and ESKD patients assessed by different diagnostic methods, either sleep questionnaires or respiration monitoring equipment [such as polysomnography (PSG), type III portable monitors or other diagnostic tools]. Single-study data were pooled using the random-effects model. The Chi
2 and Cochrane-I2 tests were used to assess the presence of heterogeneity, which was explored performing sensitivity and/or subgroup analyses. Results A cumulative analysis from 32 single-study data revealed a prevalence of SA of 57% [95% confidence interval (CI) 42%–71%] in the CKD population, whereas a prevalence of 49% (95% CI 47%–52%) was found pooling data from 91 studies in ESKD individuals. The prevalence of SA using instrumental sleep monitoring devices, including classical PSG and type III portable sleep monitors, was 62% (95% CI 52%–72%) and 56% (95% CI 42%–69%) in CKD and ESKD populations, respectively. Sleep questionnaires revealed a prevalence of 33% (95% CI 16%–49%) and 39% (95% CI 30%–49%). Conclusions SA is commonly seen in both non-dialysis CKD and ESKD patients. Sleep-related questionnaires underestimated the presence of SA in this population. This emphasizes the need to use objective diagnostic tools to identify such a syndrome in kidney disease. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
6. Kidney Fibrosis and Matrix Metalloproteinases (MMPs).
- Author
-
La Russa A, Serra R, Faga T, Crugliano G, Bonelli A, Coppolino G, Bolignano D, Battaglia Y, Ielapi N, Costa D, Michael A, and Andreucci M
- Subjects
- Humans, Animals, Renal Insufficiency, Chronic pathology, Renal Insufficiency, Chronic metabolism, Renal Insufficiency, Chronic enzymology, Matrix Metalloproteinase 9 metabolism, Kidney Diseases pathology, Kidney Diseases metabolism, Kidney Diseases enzymology, Kidney Diseases etiology, Fibrosis, Epithelial-Mesenchymal Transition, Matrix Metalloproteinases metabolism, Kidney pathology, Kidney metabolism
- Abstract
Chronic kidney disease (CKD) is a disorder that causes changes in both the structure and function of the kidneys, causing complications such as hypertension, edema, and oliguria. Renal fibrosis is also a common pathological feature of CKD. Matrix metalloproteinases (MMPs) are endopeptidases that degrade extracellular matrix (ECM) proteins. The proteinase domain consists of a zinc ion in the active site, which contributes to its stabilization with another zinc and three calcium structural ions. Many cellular processes are controlled by MMPs, such as cell-cell interactions and various signaling pathways, while they are also involved in degrading substrates on cell surfaces. Tissue inhibitors of metalloproteinases (TIMPs) are key regulators of metalloproteinases, and both are involved in regulating cell turnover, the regulation, and the progression of fibrosis and apoptosis in the tissue. MMPs play a role in renal fibrosis, such as the tubular cell epithelial-mesenchymal transition (TEM), activation of resident fibroblasts, endothelial-mesenchymal transition (EndoMT), and pericyte-myofibroblast transdifferentiation. This review aims to show the mechanisms through which MMPs contribute to renal fibrosis, paying particular attention to MMP-9 and the epithelial-mesenchymal transition., Competing Interests: The authors declare no conflict of interest. Raffaele Serra is serving as one of the Editorial Board members of this journal. We declare that Raffaele Serra had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Amancio Carnero Moya., (© 2024 The Author(s). Published by IMR Press.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.